A meta-analysis showed that genetic variations at the LPA locus are associated with CHD during statin therapy, independent of the extent of LDL lowering, providing support for exploring strategies targeting circulating concentrations of Lp(a) to reduce CHD events in patients receiving statins [51]. Here, LPA is linked to coronary artery disorder.